Acadia Healthcare Company, Inc. (NASDAQ: ACHC), a leading provider of behavioral healthcare services, witnessed a significant pre-market plunge of 15.82% in its stock price on Friday morning. This sharp decline was driven by the company's disappointing fourth-quarter 2024 financial results and lackluster full-year 2025 guidance, which fell short of analysts' expectations.
In the fourth quarter, Acadia reported revenue of $774.2 million, missing the consensus estimate of $779 million. The company's adjusted EBITDA of $153.1 million also fell short of the expected $171.4 million, despite posting a net income of $33.5 million for the quarter. Notably, Acadia's adjusted earnings per share of $0.64 missed the Zacks Consensus Estimate of $0.72.
The company's full-year 2025 guidance further dampened investor sentiment. Acadia forecasted revenue in the range of $3.3 billion to $3.4 billion and adjusted EBITDA between $675 million and $725 million. These projections fell below analysts' expectations, suggesting that the company's growth trajectory may be slowing down. Additionally, Acadia anticipated capital expenditures ranging from $525 million to $575 million, indicating significant investments to expand its psychiatric bed capacity to meet the growing demand for mental health services.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.